Superinfections with resistant micro-organisms have recently become an increasing problem in hospital patients and are thought to be contributed to by inappropriate use of newer, broad-spectrum antibiotics. Erythromycin exhibits a more limited spectrum of antibacterial activity and was therefore re-evaluated in the treatment of acute chest infections in critically ill patients. Twenty-one patients were given erythromycin in a dose of 1.8 g per day by continuous intravenous infusion for up to five days. A satisfactory clinical response occurred in ten patients, in all of whom erythromycinsensitive micro-organisms were isolated from sputum. An unsatisfactory response occurred in six patients, all associated with micro-organisms insensitive to erythromycin and requiring alternative antibiotic treatment. No undesirable side-effects were noted. It is concluded that erythromycin is a safe and useful agent in the routine treatment of acute chest infections in critically ill patients.
INTRODUCTION
The use of the newer, broad-spectrum antibiotics, especially the semi-synthetic penicillins, has become common practice in the treatment of acute chest infections. Such infections are frequently encountered in clinical practice and are a common complication in hospital patients, especially those who are seriously ill. The widespread use of these antibiotics has, however, resulted in a number of new problems, particularly the emergence of resistant micro-organisms and the consequent reduction in the efficacy of these drugs in situations in which they might otherwise have been more specifically indicated (Tillotson and Finland 1969, Tolhurst, Buckle and Williams 1972) .
Erythromycin is an antibiotic which, although widely prescribed in general practice, has been used much less in hospitals especially in recent years because of the development of newer antibiotics (Neaverson 1976 , Lacey 1977 . However, it has a number of useful properties which prompted us to reassess its value in the routine treatment of acute chest infections in seriously ill patients. These include (a) few undesirable side-effects (Neaverson 1976 , Lacey 1977 , (b) the ease of achieving therapeutic blood levels (Neaverson 1976 ), (c) good penetration into body fluids including sputum and urine (Tolhurst et al. 1972 , Neaverson 1976 , and (d) antibacterial activity which, although primarily against gram positive organisms, is also directed against Haemophilus influenzae, mycoplasmas and anaerobic gram-negative bacilli (Tolhurst et al. 1972, Tillotson and Lerner 1968) , the latter of which may be relevant in some chest infections but are not well covered by the newer, broad-spectrum antibiotics (Tillotson and Lerner 1968 , Bartlett, Rosenblatt and Feingold 1973 , Gorbach and Bartlett 1974 , Bjerkestrand, Digranes and Schreiner 1975 , Feingold 1975 .
In the present study, patients with acute chest infections in an Intensive Care Unit were treated with erythromycin empirically after suitable bacteriological specimens had been obtained, provided there was no clinical or laboratory evidence indicating that t'he use of other antibiotic regimens would be more appropriate. Erythromycin was given by continuous intravenous infusion, blood and urine levels of the drug were measured, daily microbiological examination of the sputum was made and the clinical response was recorded.
MATERIALS AND METHODS

Patients
Patients with acute chest infections in an Intensive Care Unit were selected. Chest infection was diagnosed on the basis of the production of clinically purulent sputum, with fever and leucocytosis and without evidence of infection elsewhere. Daily chest x-rays were taken but radiological signs of consolidation were not required for the diagnosis. Patients were included in the study if there was no clinical or laboratory evidence to indicate that the use of some other antibiotic regimen would b~ more appropriate.
Treatment
Erythromycin lactobionate (Erythrocin, Abbott) was given by continuous intravenous infusion in a dose of 900 mg diluted in 500 ml of isotonic saline and run over 12 hours. This treatment was continued for 5 days, unless microbiological examination of sputum showed the presence of pathogens resistant to erythromycin or intravenous medication was changed to oral treatment because of the discharge of the patient to a general ward. In all cases, routine respiratory care including oxygen, humidification and physiotherapy was given. Patients with endotracheal tubes were ventilated and had tracheobronchial suction at least hourly.
Assessment
Daily microb;ological examination of the sputum was made for respiratory pathogens and serum and urine levels of erythromycin were measured at random times. Daily measurements of serum b;ochemistry were made electrolytes, creatinine, urea, proteins, liver function tests. The index of response was the clinical assessment of resolution of chest infection, as evidenced by decreased volume and/ or degree of purulence of sputum, subsidence of fever and leucocytosis, improvement in radiological abnormalities, if any, and improvement in arterial oxygen tension. The response was classified as follows: "comnlete" (complete resolution); "incomplete" (incomplete resolution); "no change" (no resolution); "not assessable" (unchanged but treatment terminated in 48 hours or less, as indicated above). Any clinical or technical problems were recorded. 
RESULTS
There were 21 patients, 15 male and 6 female, and their ages ranged from 16-74 years (mean 47 years). The clinical details of the patients, their current diagnoses and any underlying respiratory problems are summarized in Table 1 . All patients except nos. 4, 7 and 9 were intubated. Radiological evidence of bronchopneumonia was noted in patients 2, 15 and 20.
Erythromycin was given for 1-5 days (mean 2.8 days). The mean serum concentration of erythromycin was 5.6 p.g per ml (range 1.2-13.5 p.g per ml) and the mean urine concentration was 128 p.g per ml (range 38-214 p.g per ml). Three patients had blood levels less than 2.5 p.g per ml, viz., 1.2, 1.5 and 1.6 p.g per m!. These 3 patients (nos. 16, 18 and 19) were all young males aged between 19 and 25 years and were suffering from drug overdose, 2 having taken methaqualone with diphenhydramine (Mandrax) and 1 thioridazine (Melleril). No relation could be shown between erythromycin blood levels and clinical response.
The clinical responses are summarized in Table 2 .
The clinical response was "complete" in 8 patients.
The initial microbiological examination of their sputum showed either normal flora (1 patient) or erythromycinsensitive pathogens (7 patients):pneumococci in 1, streptococci in 1, coagulase-positive staphylococci in 2, Haemophilus influenzae in 2 and klebsiella in 1. No micro-organisms were subsequently isolated from these patients. The clinical response was usually obtained early (mean 54 hours, 2.25 days).
An "incomplete" clinical response occurred in 2 patients. In both, initial sputum examination showed multiple though erythromycin-sensitive pathogens:-in one, haemophilus and staphylococci, and in the other, haemophilus, staphylococci and pneumococci. In the former, a resistant klebsiella was subsequently isolated. The clinical response in both patients was delayed up to 120 hours (5 days).
The clinical response was assessed as "no change" in 6 patients. In all, micro-organisms insensitive to ery~hromycin were isolated from their sputum and included haemophilus, coliforms and staphylococci. Antibiotic therapy Response is as defined in the text. Sensitivity/insensitivity of micro-organisms refers to erythromycin. All micro-organisms listed were isolated from initial sputum samples, except for (klebs.) in patient no. 2 which was isolated during treatment.
1. F. CADE AND M. C. F. PAIN was therefore modified according to the sensitivities demonstrated in I'i!ro. Two of these patients (nos. 6 and 7) subsequently died with extensive bronchopneumonia demonstrated at autopsy. The clinical response was "not assessable" in 5 patients. In all, sputum examination showed either normal flora or erythromycinsensitive pathogens (pneumococci or staphylococci). Based on the relation between clinical response and sputum pathogens seen in the other 16 cases, it seems likely that the response in these five cases would also have been "complete" had erythromycin infusion been ab:e to be continued.
In summary, of the clearly assessab!e results, 62.5 % (10 of 16) showed a satisfactory clinical response. Of the total group of patients, 29% (6 of 21) were treatment failures.
There was only one instance (no. 2) in which an erythromycin-resistant micro-organism (klebsiella) which had not been present initially was subsequently isolated from sputum during treatment. There was no biochemical evidence of hepatic or renal changes attributable to erythromycin, no instances of thrombophlebitis or difficulties with intravenous infusion, and no other undesirable side-effects noted.
DISCUSSION
The chemotherapeutic approach to the treatment of acute chest infections has undergone a number of changes in the past two decades. Although recent emphasis has been on the use of the newer, semi-synthetic penicillins with broad anti-microbial spectra, it has now become apparent that these arc not necessarily the best agents (Neaverson 1976 , Lacey 1977 . Firstly, they fail to eradicate a significant number of such infections (Neaverson 1976 , Lacey 1977 . Secondly, and more significantly, they may predispose to superinfection with micro-organisms, especially gram-negative bacilli, which are resistant not only to the antibiotics being used, but which frequently show multiple antibiotic resistance patterns (Tillotson and Finland 1969, Tolhurst et al. 1972 ). Both of these consequences and especially the latter are of concern in the treatment of sick hospital patients and in particular of those who arc critically ill.
The extent of these problems could perhaps b-; reduced by using an agent with a narrower and more appropriate spectrum of activity. Erythromycin is active primarily against gram-positive organisms and gram-negative cocci but not gram-negative bacilli, except haemophilus and some anaerobes, such as bacteroides (Tolhurst et al. 1972 , Lacey 1977 . It is also active against mycoplasmas (Tolhurst et al. 1972 , Lacey 1977 . Overgrowth of resistant gram-negative organisms is less likely to follow the use of erythromycin than the broad-spectrum antibiotics, such as cephalosporins or ampicillin (Lacey 1977) .
In hospital practice until approximately 10 years ago, erythromycin was usually held in reserve for the treatment of resistant staphylococcal infections and even so, the emergence of erythromycin-resistant staphylococci was a common fear, though largely unfounded (Forfar et al. 1966 , Forsell 1971 , Manners et al. 1976 , Neaverson 1976 , Lacey 1977 . When later and more effective agents became available for this purpose, such as methicillin, cloxacillin, perhaps cephalosporins and sometimes aminoglycosides or fucidic acid, erythromycin fell into relative disuse, except in patients with penicillin allergy. Erythromycin thus became a neglected antibiotic in hospital practice and many newer antibiotics which may often be less effective and more hazardous than erythromycin have come into common use (Neaverson 1976 , Lacey 1977 . It was thus considered timely to re-evaluate the use of erythromycin (Lacey 1977) , in this study for the management of acute chest infections.
In the present study, 62.5% of those patients whose response could be clearly assessed showed a satisfactory result. This response was a:,sociated with the presence of erythromycinsensitive pathogens in the sputum. In 29% of cases, micro-organisms insensitive to erythromycin were isolated from sputum and in these cases, alternative antibiotics were required. The overall clinical result was considered to be comparable with that expected from any other antibiotic regimen.
No undesirable side-effects were noted. In particular, there were no instances of thrombophlebitis or difficulties with the intravenous infusion, problems reported to occur after the intravenous injection of erythromycin. Their absence in the present study was considered to be due to the fact that the antibiotic was given diluted and by slow infusion. Blood levels of a drug are also easier to interpret when it is given by constant intravenous infusion than when it is given intermittently. Average erythromycin levels in serum were higher than those usually seen after A"ae,\"thesia and 111(('I1.\;\,(' Care. Vol. I'll, No, 2, ,\far. 1979 oral administration and were well above the minimum inhibitory concentration for most erythromycin-sensitive organisms (Neaverson 1976, Berend, RutIand and Marlin 1978) . It was of interest that the mean serum level of erythromycin of 5.6 p,g/ml was very close to the steady state concentration expected on pharmacokinetic grounds (A very 1976) , namely 5 p,g/ml, given a continuous intravenous infusion of 1 g each 12 hours and assuming an apparent volume of distribution of 0.57 l/kg, a half-life of 1.6 hours and body weight of 70 kg.
It might be added that since carrying out this study, we now use erythromycin routinely in a number of other clinical situations, particularly where infection with Bacteroides sp. is likely. These conditions include fulminating infections, especially septicaemic states, where erythromycin is used in combination with other antibiotics, usually ampicillin and gentamicin. In very severe infections, doses up to 4 g per day are given by intravenous infusion. The use of erythromycin in this situation is appealing, since it is effective and has few side-effects, whereas there is now some concern over the use of clindamycin and also lincomycin because of the complication of pseudomembranous colitis (Ball, Gray and Murdoch 1975, Smith and Goulston 1975) .
The limited experience of this study indicates that erythromycin is a safe and useful agent in the routine treatment of acute chest infections in seriously ill patients. This macrolide antibiotic has a number of advantages over others, perhaps the chief one being that it has a narrower and frequently more appropriate spectrum than many of the newer antibiotics for the treatment of chest infections. In view of the increasing emergence of multiple antibiotic resistant micro-organisms in hospital practice, the use of an antibiotic which is clinically effective and which has epidemiological advantages has considerable attraction compared to the more commonly used, broad-spectrum antibiotic regimens.
